Personalized Semaglutide+

Semaglutide is a GLP-1 receptor agonist that helps regulate blood sugar, improve insulin release, and reduce appetite. It supports sustainable weight loss by mimicking natural GLP-1 activity in the body.
‍

Eligibility:
Patients with a BMI of 30+, or 27+ with a weight-related condition (such as type 2 diabetes, high blood pressure, or high cholesterol), may qualify. Patients with a BMI above 25 may also qualify depending on their medical history.
‍

Provider Review:
Licensed providers review your intake asynchronously — meaning no live doctor visit is required. If needed, they may follow up through the secure patient portal to request additional information. Your provider will adjust your dose over time to help maximize results with minimal side effects.
‍

Process:

1. Complete your intake form securely online.
2. A licensed provider reviews your medical history asynchronously (typically within 24 hours).
3. If approved, your medication is compounded and shipped via UPS 2-Day Air.

Expectations:

• In the first few weeks, many patients notice reduced appetite and cravings.
• By 8–12 weeks, studies show meaningful weight loss and improved blood sugar control.
• At 6 months, most patients experience significant progress, with ongoing provider guidance to adjust dosage and support long-term results.

Individual results vary. Clinical outcomes referenced are from studies on the FDA-approved brand-name drug, not this compounded preparation.

This is a compounded tirzepatide preparation. It is not FDA-approved and is not the same as Mounjaro® or Zepbound®.

Important Safety Information: Compounded Semaglutide

Compounded semaglutide is not FDA-approved but may be legally prescribed by a licensed healthcare provider after a medical consultation.

Eligibility. You may qualify with a BMI of 30+, or 27+ with a weight-related condition (high blood pressure, type 2 diabetes, high cholesterol). A BMI above 25 may also qualify depending on medical history. A licensed provider reviews each case.

Indication. Semaglutide is a GLP-1 receptor agonist for chronic weight management, combined with a reduced-calorie diet and increased physical activity.

Do not use if you or a family member has a history of medullary thyroid carcinoma (MTC) or MEN 2, or if you've had a severe allergic reaction to semaglutide.

Warnings. Report any of the following to your provider immediately: neck lumps, hoarseness, or trouble swallowing (thyroid risk); severe abdominal pain (pancreatitis); jaundice or clay-colored stools (gallbladder); low blood sugar symptoms; facial/throat swelling or difficulty breathing; and any new or worsening depression, mood changes, or suicidal thoughts.

Before starting, tell your provider if you have pancreas or kidney problems, diabetic retinopathy, are pregnant/breastfeeding (not recommended), or are taking other medications or supplements.

Administration. Once-weekly subcutaneous injection in the stomach, thigh, or upper arm. Do not adjust or stop without consulting your provider.

Common side effects include nausea, diarrhea, constipation, abdominal pain, headache, fatigue, and dizziness.

Treatment must be monitored by a licensed provider. For emergencies, call 911. For safety reporting, contact FDA MedWatch at 1-800-FDA-1088 or visit fda.gov/medwatch.

For more information, see full prescribing and safety details.